HIP
BMRN icon

Hatteras Investment Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hatteras Investment Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-12,994
Closed -$1.62M – 112
2015
Q1 		$1.62M Buy
+12,994
New +$1.38M 0.87% 41

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Hatteras Investment Partners's BMRN Position: Q2 2015 in Review

Hatteras Investment Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 12,994 shares — an estimated $1.62M sold.

Hatteras Investment Partners first reported a position in BMRN in Q1 2015 and held it in 1 quarter. The position peaked at $1.62M in Q1 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

  • Hatteras Investment Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Hatteras Investment Partners sold 12,994 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $1.62M.
  • Hatteras Investment Partners first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Hatteras Investment Partners's BioMarin Pharmaceuticals position peaked at $1.62M in Q1 2015.
  • 391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Hatteras Investment Partners's 13F filing for Q2 2015, filed 13 Aug 2015.